In human BC, EGFR overexpression is commonly linked to HER2 overexpression [4], HER2 positivity being a predictive marker for treatment with specific HER2-targeted therapies, e.g. trastuzumab [8]. This evidence concerns the gene ERBB2 and breast cancer.